Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 25, 2025Liver CancerOpen Access

Surrogate endpoints for overall survival in advanced hepatocelluar carcinoma in the era of immunotherapy: a trial level meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

YSYacob SalehZBZeynep BaskurtAFAbdul Rehman Farooq

Discussion

Loading...

Member takes

Overview

Meta-analysis examines the relationship between progression-free survival and overall survival in advanced HCC, suggesting implications for endpoint selection in trials.

Key Points

  • A weak correlation exists between HR-PFS and HR-OS in 1st-line RCTs in advanced HCC, indicating OS should remain the primary endpoint.
  • The analysis included 21 1st-line and 12 2nd-line RCTs, with 48% assessing ICIs alone or in combination for overall survival.
  • A strong association between HR-PFS and HR-OS was found in 2nd-line RCTs, suggesting PFS may be an appropriate primary endpoint for these patients.
  • Subgroup analysis uncovered a moderate correlation between HR-PFS and HR-OS in 1st-line RCTs with fewer patients of non-viral etiology, highlighting variances in endpoint applicability.

Cite This Study

Saleh et al. (2025) studied this question.

synapsesocial.com/papers/68d5d0feddad3c16d4635f90https://doi.org/10.1159/000548606
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched one closely related paper. Consider it for comparative context:

  1. 1The PRISMA 2020 statement: an updated guideline for reporting systematic reviews2021 · 106,426 citations